Open an account

Vertex Pharmaceuticals

VRTX · NASDAQ

$514.65+$12.70 (+2.53%)TodayMarket closed ·
Prev close $501.95

About VRTX

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The company is headquartered in Boston, Massachusetts and currently employs 6,400 full-time employees. The company has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).

Employees
6,400
Headquarters
Boston, Massachusetts
Listed
Jul 24, 1991
Sector
Health Care
Industry
Biotechnology
Website
vrtx.com

VRTX key statistics

Market cap
126.66B
Price-earnings ratio
29.23
Dividend yield
—
Average volume
1.19M
Volume
911.00K
Open price
$507.89
High today
$515.74
Low today
$505.00
52 Week high
$560.25
52 Week low
$403.16

Vertex Pharmaceuticals (VRTX) at a glance

As of Oct 20, 2026, Vertex Pharmaceuticals (VRTX) shares are priced at $514.65, giving the company a market cap of 126.66B and a price-to-earnings ratio of 29.23.

Today the stock has traded between $505.00 and $515.74. The current price is 1.9% above the day's low and 0.2% below its high.

Volume so far is 911.00K shares, below the average of 1.19M shares a day.

Over the past year Vertex Pharmaceuticals has ranged from $403.16 to $560.25, and now sits 71% of the way up that range.

Vertex Pharmaceuticals met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported $4.73 per share against an estimate of $4.83.

The average analyst price target is $583.37, 13.4% above the current price, from 26 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

81%of 26 analyst ratings say Buy
  • Buy80.8%
  • Hold15.4%
  • Sell3.8%
Price target · 31 analystsAvg $583.37
Low
$353.50
Now
$514.65
High
$705.60

VRTX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 3.0% on average.

  1. Q3 FY24: reported $4.38 per share against an estimate of $4.22
  2. Q4 FY24: reported $3.98 per share against an estimate of $4.11
  3. Q1 FY25: reported $4.06 per share against an estimate of $4.37
  4. Q2 FY25: reported $4.52 per share against an estimate of $4.37
  5. Q3 FY25: reported $4.80 per share against an estimate of $4.65
  6. Q4 FY25: reported $5.03 per share against an estimate of $5.17
  7. Q1 FY26: reported $4.47 per share against an estimate of $4.40
  8. Q2 FY26: reported $4.73 per share against an estimate of $4.83

VRTX news

  • Press releaseBusiness Wire

    Vertex Appoints Daniel Brennan to its Board of Directors

  • Press releaseBusiness Wire

    Vertex to Present New Data on ALYFTREK® at the North American Cystic Fibrosis Conference

  • Press releaseBusiness Wire

    Vertex to Announce Third Quarter 2026 Financial Results November 2nd

  • Piero Cingari

    Nasdaq 100 Records Have Rarely Been This Narrow, 55 Stocks Are Still Below 50-Day Average

  • Vandana Singh

    Vertex Touts Encouraging Data From 'Underappreciated' Kidney Drug

  • Press releaseBusiness Wire

    Vertex Announces Positive Results From Phase 2b AMPLIFIED Study of Inaxaplin in Additional Populations of People With APOL1-Mediated Kidney Disease (AMKD) and Completion of Enrollment in the Phase 2/3 AMPLITUDE Trial

  • Press releaseBusiness Wire

    Vertex Partners With World Champion Skier Lindsey Vonn to Raise Awareness of JOURNAVX®, a Non-Opioid Medicine Approved for the Treatment of Moderate-to-Severe Acute Pain

  • Press releaseGlobe Newswire

    Replacing Insulin Cells Works. Keeping The Cells Alive Is the Trick

Similar companies

Companies in the same industry as Vertex Pharmaceuticals

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.